1. Weitzel, KW, Alexander, M, Alexander, M, et al. The IGNITE network: a model for genomic medicine implementation and research. BMC Med Genomics. 2016;9:1. doi:10.1186/s12920-015-0162-5
Google Scholar | Crossref | Medline2. Imagenetics . Home - Imagenetics; 2017. [online] Available at: http://imagenetics.sanfordhealth.org/patient-care/pharmacogenetics-testing/. Accessed January 9, 2017.
Google Scholar3. Larson, EA, Wilke, RA. Integration of genomics in primary care. Am J Med. 2015;128(11):1251.e1. Epub May 30, 2015. doi:10.1016/j.amjmed.2015.05.011
Google Scholar | Crossref4. Yang, Q, Cogswell, ME, Flanders, WD, et al. Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults. J Am Med Assoc. 2012;307(12):1273-1283. doi:10.1001/jama.2012.339
Google Scholar | Crossref | Medline | ISI5. Fuster, V, Badimon, L, Badimon, JJ, Chesebro, JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med. 1992;326(5):310-318. doi:10.1056/NEJM199201303260506
Google Scholar | Crossref | Medline | ISI6. Airoldi, F, Colombo, A, Morici, N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation. 2007;116(7):745-754. doi:10.1161/CIRCULATIONAHA.106.686048
Google Scholar | Crossref | Medline7. Spertus, JA, Kettelkamp, R, Vance, C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation. 2006;113(24):2803-2809. doi:10.1161/CIRCULATIONAHA.106.618066
Google Scholar | Crossref | Medline8. Leon, MB, Baim, DS, Popma, JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent anticoagulation restenosis study investigators. N Engl J Med. 1998;339(23):1665-1671. doi:10.1056/NEJM199812033392303
Google Scholar | Crossref | Medline | ISI9. Valgimigli, M, Bueno, H, Byrne, RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European society of cardiology (ESC) and of the European association for cardio-thoracic surgery (EACTS). Eur Heart J. 2018;39(3):213-260. doi:10.1093/eurheartj/ehx419
Google Scholar | Crossref | Medline10. Levine, GN, Bates, ER, Bittl, JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016;134(10):e123-e155. Erratum in: Circulation. 2016 Sep 6;134(10):e192-4. PMID: 27026020. doi:10.1161/CIR.0000000000000404
Google Scholar | Crossref | Medline | ISI11. Scott, SA, Sangkuhl, K, Stein, CM, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94(3):317-323. Epub May 22, 2013. doi:10.1038/clpt.2013.105
Google Scholar | Crossref | Medline | ISI12. Mao, L, Jian, C, Changzhi, L, et al. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects. Arch Cardiovasc Dis. 2013;106(10):517-527. Epub September 27, 2013. doi:10.1016/j.acvd.2013.06.055
Google Scholar | Crossref | Medline13. Mega, JL, Simon, T, Collet, J-P, et al Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. J Am Med Assoc. 2010;304(16):1821-1830. 10.1001/jama.2010.1543
Google Scholar | Crossref | Medline14. Mega, JL, Close, SL, Wiviott, SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354-362. doi:10.1056/NEJMoa0809171
Google Scholar | Crossref | Medline | ISI15. Mega, JL, Hochholzer, W, Frelinger, AL, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. J Am Med Assoc. 2011;306(20):2221-2228. Epub November 16, 2016. doi:10.1001/jama.2011.1703
Google Scholar | Crossref | Medline16. Cavallari, LH, Franchi, F, Rollini, F, et al. Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention. J Transl Med. 2018;16(1):92. doi:10.1186/s12967-018-1469-8
Google Scholar | Crossref | Medline17. Aleil, B, Jacquemin, L, De Poli, F, et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. JACC Cardiovasc Interv. 2008;1(6):631-638. doi:10.1016/j.jcin.2008.09.004
Google Scholar | Crossref | Medline18. Xiong, R, Liu, W, Chen, L, Kang, T, Ning, S, Li, J. A randomized controlled trial to assess the efficacy and safety of doubling dose clopidogrel versus ticagrelor for the treatment of acute coronary syndrome in patients with CYP2C19*2 homozygotes. Int J Clin Exp Med. 2015;8(8):13310-13316.
Google Scholar | Medline19. Stanek, EJ, Sanders, CL, Taber, KAJ, et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther. 2012;91(3):450-458. Epub January 25, 2012. doi:10.1038/clpt.2011.306
Google Scholar | Crossref | Medline | ISI